Abstract 5-HT 3 receptors are members of the Cys-loop superfamily of ligand-gated ion channels. In both the central and the peripheral nervous systems, 5-HT 3 receptors excite postsynaptic cells and modulate the release of neurotransmitters from presynaptic neurons. 5-HT 3 receptors are known to be involved in mediation of nausea/emesis caused by chemo/radio-therapy and anaesthesia, and more recently have also been found to be involved in irritable bowel syndrome. 5-HT 3 receptors have also been suggested to play a role in a range of other indications, including various psychiatric disorders. This review summarizes the current evidence for the contribution of 5-HT 3 subunit genes to disease phenotypes arising from association studies. Furthermore, it suggests how in vitro characterization of naturally occurring genetic variants can be used to obtain a better understanding of the causal relationship between gene and disease.
5-HT (5-hydroxytryptamine) is one of the major neurotransmitters in both the central and the peripheral nervous systems, exerting its fast excitatory neuronal responses via activation of the only known 5-HT-gated ion channel, the 5-HT 3 receptor. The 5-HT 3 receptor is further expressed at presynaptic locations, where it mediates neurotransmitter release. Extraneuronal locations of the 5-HT 3 receptor include various cells of the immune system.
The physiological role of 5-HT 3 receptors remains elusive. Nevertheless, the use of 5-HT 3 receptor antagonists is well established in the treatment of chemo/radio-therapy-induced emesis and post-operative nausea and vomiting. More recently, 5-HT 3 antagonists have been found to be clinically relevant in treatment of diarrhoea-predominant irritable bowel syndrome [1] . In addition, 5-HT 3A -knockout mice have been shown to display an anxiolytic phenotype [2] , and the receptor has been suggested to be involved in the pathogenesis of other psychiatric disorders, in alcohol/drug abuse, in certain pain disorders and in the regulation of food intake/ satiety [1] .
The 5-HT 3 receptor belongs to the Cys-loop superfamily of ligand-gated ion channels, which also includes receptors for acetylcholine, GABA (γ -aminobutyric acid) and glycine [3] . All members of this family share the same overall architecture, arising from the assembly of five subunits forming a central ion-conducting pore. Each subunit transverses the cell membrane four times, displaying both N-and C-termini on the extracellular side and ligand-binding sites formed at the interfaces of adjacent N-terminal domains [3] . The second TM (transmembrane) regions line the ion pore, and ion selectivity and conductance are controlled by the pore region (TMII), TMI-TMII (selectivity) and TMIII-TMIV (conductance) [4] .
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Five different subunits, A-E, of the 5-HT 3 receptor have been identified, of which the biological significance of subunits C-E remains to be determined. 5-HT 3A subunits are capable of forming functional homomeric receptors, whereas 5-HT 3B subunits are retained within the endoplasmic reticulum unless rescued by co-assembly with 5-HT 3A subunits [5] . The major difference between homomeric 5-HT 3A and heteromeric 5-HT 3A/3B receptors is their biophysical properties (particularly conductance), with only minor differences in their pharmacological characteristics [6] .
Naturally occurring variations in the genes coding for 5-HT 3 subunits may affect the function and/or the expression of the 5-HT 3 receptors, thereby potentially affecting 5-hydroxytryptaminergic signalling and predisposing individuals to diseases or affecting the severity or the treatment efficacy of diseases. The mapping of the human genome has revealed a genetic variability between human beings of almost 0.1%, most of the variation accounted for by single nucleotide polymorphisms. Variations within the regulatory region of a gene and those causing changes in the amino acid sequence of the encoded protein (either missense variations or alternative use of splice sites, leading to premature truncation or shift in the reading frame) are likely to affect the expression, stability and/or the function of the protein. Variations in the coding region that do not affect the amino acid sequence (i.e. being silent) may still exert an effect on the stability of the transcript and thereby affect the expression level of the protein. This review will, however, focus on regulatory and missense coding polymorphs as these are thought to display the largest impact.
Association studies have been carried out to establish causal relationships between genetic variation in the genes encoding 5-HT 3A and 5-HT 3B and disease or treatment efficacy. Genotyping of patients and controls has led to the identification of numerous variations; those localized to regulatory regions and those causing a change in the protein sequence are summarized in Table 1 . A recent study showed Regulatory region del-variant less frequent in BP pts compared with ctrls [8] Predicted change in [8, 17] RNA secondary structure [8] del/del carriers displayed trend towards increased - [12] vomiting following chemotherapy and treatment with *The lowest and highest allelic frequencies found are given when determined in more than one association study or one ethnic group. †This variant is also known as 5 -UTR (5 -untranslated region) C195T and was exclusively detected in combination with -42C > T in the same allele. ‡This variant is also known as 5 -UTR C178T and upstream open reading frame P16S. §This variant is also known as S533R.
an association between major depression in women and a haplotype block in the 5-HT 3B gene [7] . This haplotype block included one polymorphism that caused an amino acid change, Y129S. This polymorphism is very common (displaying allelic frequencies of 0.11-0.44 in four major ethnic groups) and was found to be significantly less frequent in females with major depression, suggesting a protective effect of the variant allele. The Ser 129 variant has also been shown to be less frequent in patients with bipolar affective disorder [8] . The same study also associated two other variants of the 5-HT 3B gene (-100-102delAAG and V183I) with bipolar disorder, further strengthening the involvement of 5HT 3B . Likewise, a common variation in the regulatory region of the 5-HT 3A gene (-42C > T) has been associated with bipolar affective disorder in Caucasians [9] . A recent study on Japanese patients did not, however, confirm the latter study [7] . The -42T/-42T genotype has further been associated with lower harm avoidance in women, an association that was strengthened by replication of the finding in a second sample [10] . Further, associations between polymorphisms in the genes coding for 5-HT 3 and the severity of nausea/emesis following chemotherapy and treatment with 5-HT 3 antagonists have been investigated. Interestingly, trends were found only between emetogenic level and one polymorphism of 5-HT 3A (M257I) [11] and two of 5-HT 3B (-100-102delAAG and Y129S) [12] , whereas the latter variant Y129S has also been found to be associated with paroxetineinduced nausea [13] .
A number of caveats should of course be borne in mind when interpreting association studies. A polymorphism may exist in linkage disequilibrium with another variation not investigated, which is actually the one responsible for the phenotype. On the other hand, a true association may not be detected for a low-frequent variant due to low power of the study. Also, the cause of complex disorders is likely to be multigenetic, possibly with contributing non-genetic factors. In relation to studies on treatment efficacy, pharmacokinetic variability should be assessed as well as the pharmacodynamic variability. Investigation of the functional effects of polymorphisms in vitro may help strengthen association studies in offering a putative mechanistic explanation to support the findings of association studies. They may also be used in the design of certain focused studies exploiting association between one or several functionally similar variants and a particular phenotype, thus increasing the power of the studies.
The functional implications at the molecular level of most of the polymorphisms of the genes coding for 5-HT 3A and 5-HT 3B are unknown. Two studies have been published, one reporting that the variation in the regulatory region of 5-HT 3A , -42C > T, strongly increases gene expression in vitro [9] and the other showing a completely wild-type-like profile of the 5-HT 3A variant P391R [14] . An in vitro characterization of the other variants may help us to understand which features at the molecular level (e.g. a decreased signalling) may be the cause or contributing factor to a certain disease phenotype. Such an understanding may subunits The variant amino acids (shown in white) are modelled on the 4 Å structure of the T. marmorata acetylcholine receptor (PDB entry 2BG9) [15] using RasMol v2.6 [16] . Acetylcholine receptor subunits are shown with αs in red, β in blue, γ in green and δ in yellow. The aligned position of the variant residues in each subunit is shown. Owing to the low resolution of parts of the intracellular region, the position of the 5-HT 3A variants R344H, P391R and R409Q cannot be modelled; the residue 337 is highlighted (white) to indicate the approximate location of the residue 344. Purple residues in the magnification give the location of the residues Arg 432 , Arg 436 and Arg 440 . Arrows indicate the positions of residues that are almost buried within the receptor structure. Numbering of the variant residues starts with the first amino acid of the signal sequences.
form the basis of medical intervention; by knowing the genotype of a patient, a personalized treatment regime can be designed to counteract the change in signalling/expression caused by the variant.
Knowledge of the location of variant residues within the structure of the receptor may give an indication of its potential effects on receptor biogenesis or function. The recent 4 Å (1 Å = 0.1 nm) resolution of the Torpedo marmorata acetylcholine receptor [15] allows for an approximation of these locations by molecular modelling based on receptor homology (Figure 1) . Variation in the vicinity of the ligandbinding site (e.g. the 5-HT 3B variant S156R) may impinge on receptor function, as may residues lining the ion-conducting pathway. Unfortunately, the three 5-HT 3A variants located in the large intracellular loop cannot be modelled due to the low resolution in this region. Despite this caveat, R344H is predicted to be in the vicinity of the intracellular portals, of which three putative lining arginine residues have been shown to be of major importance to the conductance of the 5-HT 3A receptor [4] . If this speculative model is correct, the R344H variant might increase the conductance of the channel by reducing the positive charge of the portal linings. Furthermore, variant residues located in the interface of adjacent subunits (e.g. 5-HT 3B variants Y129S and A223T) may affect the biogenesis of the receptor by perturbing essential subunit interactions. Thus molecular modelling provides testable hypotheses as to how these polymorphisms might have an impact on receptor function; evidence of such roles needs to be determined experimentally.
In conclusion, naturally occurring variations may provide a valuable tool for elucidating gene-disease relationships.
In vitro characterization of variants may help to focus association studies to variants displaying a change in function as a means to increase the power of such an approach, which is of particular relevance when assessing low-frequency variants. Several association studies suggest an involvement of 5-HT 3 in susceptibility to psychiatric disorders, and potentially in the adverse effects, such as nausea, induced by antidepressant treatment. Further, variants of 5-HT 3 may affect the emetogenic level following chemotherapy. If the molecular mechanisms of variants linked to disease can be elucidated, this will aid and focus the search for medical treatment of the disease. An individualized treatment/dosage regime based on the genetic profile of 5-HT 3 may diminish the adverse effects of cancer therapy and thus improve the quality of life of cancer patients.
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